Evidence map›Paper›PMID 41795244›Full record

ArticleMolecular pharmacology2026

Differential impacts of exon 1-associated and exon 11-associated variants of the rat mu opioid receptor gene, Oprm1, on buprenorphine- and morphine-induced analgesia and respiratory depression in male rats.

Tiffany Zhang, Jin Xu, Valerie P Le Rouzic, Yudelca Ogando, Ayma F Malik, Raymond Chien, Miyasaka Yoshiki, Tomoji Mashimo, Thomas L Saunders, Channabasavaiah B Gurumurthy and 1 more

Abstract read
In one paragraph

Article in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tiffany ZhangDepartment of Neurology and Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Jin XuDepartment of Neurology and Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Anesthesiology, New Jersey Medical School, Newark, New Jersey; Rutgers Addiction Research Center, Brain Health Institute, Rutgers Health, Piscataway, New Jersey.
Valerie P Le RouzicDepartment of Neurology and Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Yudelca OgandoDepartment of Neurology and Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Ayma F MalikDepartment of Anesthesiology, New Jersey Medical School, Newark, New Jersey; Rutgers Addiction Research Center, Brain Health Institute, Rutgers Health, Piscataway, New Jersey.
Raymond ChienDepartment of Anesthesiology, New Jersey Medical School, Newark, New Jersey; Rutgers Addiction Research Center, Brain Health Institute, Rutgers Health, Piscataway, New Jersey.
Miyasaka YoshikiInstitute of Experimental Animal Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tomoji MashimoInstitute of Experimental Animal Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan. Electronic address: mashimo@ims.u-tokyo.ac.jp.
Thomas L SaundersTransgenic Animal Core, University of Michigan, Ann Arbor, Michigan; Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: tsaunder@umich.edu.
Channabasavaiah B GurumurthyMouse Genome Engineering Core Facility, University of Nebraska Medical Center, Omaha, Nebraska; Department of Cell and Molecular Biology, School of Medicine, University of Mississippi Medical Center, Jackson, Mississippi. Electronic address: cgurumurthy@umc.edu.
Ying-Xian PanDepartment of Neurology and Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Anesthesiology, New Jersey Medical School, Newark, New Jersey; Rutgers Addiction Research Center, Brain Health Institute, Rutgers Health, Piscataway, New Jersey. Electronic address: yx.pan@rutgers.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR01DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 1991 to 2022
$6.0M
ANALYSIS OF TOBACCO DEPOSITIONS AND TRIAL TESTIMONYR01CA087486 · NCI · MICHIGAN PUBLIC HEALTH INSTITUTE · PI DAVIS, RONALD M · 2000 to 2003
$2.8M
Rutgers Training in Addiction Research ProgramT32DA055569 · NIDA · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Robert Christopher Pierce · 2023 to 2026
$1.6M
Exploring function of mu opioid receptor splice variants in rat by gene targetingR21DA040858 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2016 to 2017
$471k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA087486NIDA NIH HHS R01 DA007242NIDA NIH HHS R21 DA040858NIDA NIH HHS T32 DA055569
6 · The paper itself

Abstract

Buprenorphine has long been recognized as a mu opioid agonist with a distinctive and intricate pharmacological profile. It is a partial agonist at the mu opioid receptor, an antagonist at the kappa and delta opioid receptors, and an agonist at the nociception opioid receptor. Similar to other mu agonists such as morphine and fentanyl, buprenorphine can produce side effects, including tolerance, physical dependence, respiratory depression, and addiction. The mu opioid receptor gene, OPRM1, undergoes extensive alternative splicing, generating an array of splice variants or isoforms, which are conserved from rodents to humans. These splice variants can be categorized into 2 main types, exon 1 (E1)-associated variants and exon 11 (E11)-associated variants. E1-associated variants primarily consist of full-length, 7-transmembrane C-terminal variants, whereas E11-associated variants are typically truncated 6-transmembrane variants. Previous studies established that buprenorphine analgesia in mice is dependent on both E1- and E11-associated variants. However, the role of these variants in buprenorphine analgesia and respiratory depression in rats remains unclear. In this study, we used CRISPR/Cas9 technology to develop 2 rat Oprm1 gene-targeting models in which E1- and E11-associated variants were selectively disrupted, aiming to investigate their roles in buprenorphine and morphine's actions. The results showed that both E1- and E11-associated variants are essential for buprenorphine's analgesic and respiratory depressional effects in rats, whereas morphine's effects are solely attributed to the E1-associated variants. These findings provide new and important insights into the distinct contributions of the E1- and E11-associated variants to the pharmacological actions of buprenorphine and morphine. SIGNIFICANCE STATEMENT: Differential dependences of buprenorphine and morphine analgesia and respiratory depression on Oprm1 exon 1- and exon 11-associated variants revealed in rat gene-targeting models provide new and important insights into unique contributions of these variants to buprenorphine and morphine actions.

Indexed as

Analgesics, OpioidBuprenorphineExonsMorphineReceptors, Opioid, muRespiratory InsufficiencyAlternative SplicingAnalgesiaAnimalsMaleRatsRats, Sprague-DawleyAnalgesics, OpioidBuprenorphineMorphineOprm1 protein, ratReceptors, Opioid, muAlternative splicingAnalgesiaBuprenorphineMorphineMu opioid receptorRespiratory depression

Identifiers

PMID41795244
PMCPMC13197947

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.